From October 1, 2024 to January 10, 2025, the company has repurchased 735,055 shares, representing 0.16% for $19.45 million. With this, the company has completed the repurchase of 17,175,055 shares, representing 3.82% for $503.91 million under the buyback announced on March 28, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.85 USD | +1.51% |
|
+1.86% | +28.77% |
Feb. 12 | Biogen Expects Decline in 2025 Revenue, Reports Fourth-Quarter Beat | MT |
Feb. 12 | Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D | MT |
Stocks mentioned in the article
Price |
Change |
5d. change |
Capi. | ||
---|---|---|---|---|---|
6,129.58PTS | +0.24% | +1.01% | - | ||
32.85USD | +1.51% | +1.86% | 14.02B | ||

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RPRX Stock
- News Royalty Pharma plc
- Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.